HLB Co., Ltd.
028300
Pozycja w akcjach
#4147
HLB Co., Ltd. operates in two distinct sectors: pharmaceutical production and... HLB Co., Ltd. operates in two distinct sectors: pharmaceutical production and naval construction. In South Korea, its maritime division produces and distributes a diverse range of lifeboats, catering to offshore platforms, drilling vessels, and passenger cruise liners. Its offerings include traditional, free-fall, and rescue boat designs. Beyond lifeboats, HLB's product portfolio extends to marine and yacht engines, hooks, and a variety of specialized vessels such as rigid inflatable (RIB), patrol, fishing, aluminum, and leisure boats, as well as fishery inspection ships and general safety equipment. The company further offers comprehensive support services, including inspection and repair of lifeboats and davits, service engineering training, and the provision of spare parts. On the pharmaceutical front, HLB is engaged in the development of Riboseranib, a targeted anti-cancer agent, and Apilia, a treatment specifically for ovarian cancer. Established in 1975, HLB Co., Ltd. is headquartered in Ulsan, South Korea.
Cena akcji
$29.28
Kapitalizacja rynkowa
$3.89B
Zmiana (1 dzień)
-1.40%
Zmiana (1 rok)
-8.45%
Kraj
KR
Handel HLB Co., Ltd. (028300)
Kategoria
Healthcare
Zyski dla HLB Co., Ltd. (028300)
Zyski w Jun 2026 TTM: $-160.32M
Według najnowszych raportów finansowych HLB Co., Ltd., obecny zysk firmy wynosi $-160.32M. W roku 2023 firma osiągnęła zysk w wysokości $-164.38M, spadek w porównaniu do zysku z roku 2022, który wynosił $-62.61M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy HLB Co., Ltd. od 2012 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $-160.32M | 115.74% |
| 2024 | $-74.31M | -54.79% |
| 2023 | $-164.38M | 162.55% |
| 2022 | $-62.61M | -27.09% |
| 2021 | $-85.87M | 12.36% |
| 2020 | $-76.43M | 43.17% |
| 2019 | $-53.38M | -540.23% |
| 2018 | $12.13M | -138.75% |
| 2017 | $-31.29M | 69.49% |
| 2016 | $-18.46M | -310.93% |
| 2015 | $8.75M | -632.68% |
| 2014 | $-1.64M | -80.80% |
| 2013 | $-8.56M | 40.17% |
| 2012 | $-6.11M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $5.27B | -3,390.24% |
US
|
|
| $-3.09B | 1,825.53% |
US
|
|
| $-4.02B | 2,405.12% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,316.72% |
NL
|
